Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Large Growth in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 157,346 shares, an increase of 52.5% from the February 26th total of 103,151 shares. Based on an average trading volume of 507,332 shares, the short-interest ratio is presently 0.3 days. Approximately 4.2% of the company’s shares are short sold.

Capstone Therapeutics Stock Performance

Shares of CAPS stock opened at $0.63 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35. The company’s fifty day moving average price is $0.64 and its two-hundred day moving average price is $0.86. The firm has a market capitalization of $5.75 million, a P/E ratio of -0.67 and a beta of -1.23. Capstone Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.29.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics as of its most recent SEC filing. 2.55% of the stock is owned by institutional investors and hedge funds.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.